The frequent association between coronavirus disease 2019 (COVID-19) and olfactory dysfunction is creating an unprecedented demand for a treatment of the olfactory loss. Systemic corticosteroids have been considered as a therapeutic option. However, based on current literature, we call for caution using these treatments in early COVID-19-related olfactory dysfunction because: (1) evidence supporting their usefulness is weak; (2) the rate of spontaneous recovery of COVID-19-related olfactory dysfunction is high; and (3) corticosteroids have well-known potential adverse effects. We encourage randomized placebo-controlled trials investigating the efficacy of systemic steroids in this indication and strongly emphasize to initially consider smell training, which is supported by a robust evidence base and has no known side effects.

• MeSH
• celosvětové zdraví MeSH
• čichová sliznice účinky léků   virologie   MeSH
• COVID-19 * komplikace   patofyziologie   MeSH
• hormony kůry nadledvin farmakologie   MeSH
• lidé MeSH
• management farmakoterapie normy   statistika a číselné údaje   MeSH
• nežádoucí účinky léčiv diagnóza   etiologie   prevence a kontrola   MeSH
• odhad potřeb MeSH
• poruchy čichu * farmakoterapie   epidemiologie   etiologie   MeSH
• SARS-CoV-2 patogenita   MeSH
• spontánní remise MeSH
• výzkumný projekt MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH